NCT05849298: An ongoing trial by Novartis Pharmaceuticals
This trial is ongoing. It must report results 1 year, 6 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT05849298 |
|---|---|
| Title | An International Prospective Open-label, Multi-center, Randomized, Non-comparative Phase II Study of Lutetium [177Lu] Vipivotide Tetraxetan (AAA617) Alone and Lutetium [177Lu] Vipivotide Tetraxetan (AAA617) in Combination With Androgen Receptor Pathway Inhibitors in Patients With PSMA PET Scan Positive Castration-Resistant Prostate Cancer |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Jan. 3, 2024 |
| Completion date | Dec. 23, 2026 |
| Required reporting date | Dec. 23, 2027, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | June 19, 2026 |
| Days late | None |